Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results in motor neuron death and has no approved treatment yet. Around 20% of ALS cases are caused by Cu, Zn human superoxide dismutase (SOD1) aggregation into amyloid-like fibrils. Wild type SOD1 is found to play the key role in the development of sporadic ALS (90% of ALS cases) [1], as well as co-aggregated with mutant SODs in familial ALS (fALS) [2]. However, most of research done in this field is based on fALS-associated mutant SODs, while inherited type of the disease comprises to only 10% of ALS cases.
We tested various aggregation conditions and found out that for aggregation into amyloid-like fibrils in vitro, SOD1 must first be reduced and partially denatured. The conditions were optimized to get rapid and repeatable aggregation kinetics. Following conditions were used for further studies: 0.2 mM concentration of monomeric SOD1, 0.5 M of GuHCl, 5 mM of DTT and 0.02 mM of SOD1 in amyloid-like form (seeds).
The effect of ethanol was the most exciting of further results. It was found to be an inhibitor of SOD1 aggregation in vitro. This trend agrees with the recent data [3], where inverse correlation between alcohol consumption disorders and risk of ALS was determined.